Form 4: Olema Pharmaceuticals Director Sandra Horning Acquires Stock Options

Olema Pharmaceuticals Director Sandra Horning has acquired 24,150 stock options with an exercise price of $4.08, vesting over 12 months or by the next annual meeting.

Summary

• Sandra Horning, a Director of Olema Pharmaceuticals, Inc. (OLMA), acquired stock options.
• The transaction date for the option grant was June 11, 2025.
• The options grant the right to buy 24,150 shares of Olema Pharmaceuticals Common Stock.
• The exercise price for these stock options is $4.08 per share.
• The stock options are set to expire on June 11, 2035.
• The shares subject to the option will vest in 12 successive equal monthly installments, measured from June 11, 2025, contingent upon Ms. Horning's continuous service.
• Full vesting will also occur on the date of the Issuer's next annual meeting of stockholders if the option is not otherwise fully vested by that date, subject to continuous service.

Sentiment

Score: 7

Explanation: The acquisition of stock options by a director is generally viewed positively as it aligns the director's interests with those of shareholders and indicates continued commitment to the company, without implying any immediate negative financial implications.

Positives

• Director Sandra Horning's acquisition of 24,150 stock options may signal confidence in Olema Pharmaceuticals' future performance and aligns her interests with shareholders.
• The long expiration date of June 11, 2035, provides a significant window for potential value realization from the options.

Negatives

• No direct negatives are apparent from the acquisition of stock options by a director, as this is a standard compensation mechanism.

Risks

• The value of the stock options is contingent on Olema Pharmaceuticals' stock price exceeding the $4.08 exercise price; if the stock price remains below this, the options may hold no intrinsic value.
• Vesting of the options is subject to the reporting person's continuous service, meaning the options could be forfeited if service terminates before full vesting.

Future Outlook

The vesting schedule for the stock options, extending over 12 months or until the next annual meeting, indicates an expectation of continued service from Director Sandra Horning, aligning her long-term commitment with the company's performance.

Management Comments

• "The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 11, 2025, subject to the Reporting Person's continuous service through each applicable vesting date."
• "Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date."

Industry Context

This Form 4 filing is a routine disclosure for insider transactions, common across all publicly traded companies, reflecting standard equity compensation practices for directors. It provides transparency regarding changes in beneficial ownership by company insiders.

Comparison to Industry Standards

• The grant of stock options to a director is a common form of equity compensation in the biotechnology and pharmaceutical industry, aligning director incentives with shareholder value creation.
• The specific size of the grant (24,150 options) and the exercise price ($4.08) would typically be evaluated against peer company compensation practices and the company's overall compensation philosophy, though specific comparable companies or projects are not detailed in this filing.

Related Party Transactions

• The grant of 24,150 stock options to Director Sandra Horning is a related party transaction, representing equity compensation from the issuer to a member of its board.

Stakeholder Impact

• Shareholders: The grant of stock options to a director aligns their interests with shareholders, as the options' value increases with the company's stock price, potentially incentivizing actions that enhance shareholder value.
• Director (Sandra Horning): Receives equity compensation, incentivizing long-term commitment and performance tied to the company's stock performance.

Next Steps

• Continued service of Sandra Horning to ensure the vesting of the stock options.
• Future SEC filings (Form 4) will report any exercises or sales of these options by the reporting person.

Key Dates

Keywords

Olema Pharmaceuticals, OLMA, Form 4, stock option, insider transaction, director compensation, equity grant, vesting